Hepion pharmaceuticals announces reverse stock split

Shares expected to begin trading on split-adjusted basis on march 18, 2025 morristown, n.j., march 14, 2025 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq: hepa), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis (“nash”), hepatocellular carcinoma (“hcc”), and other chronic liver diseases, today announced that it will implement a 1-for-50 reverse split of the issued shares of its common stock, effective at 4:01 p.m.
HEPA Ratings Summary
HEPA Quant Ranking